Jaguar Health, Inc. (JAGX)
NASDAQ: JAGX · Real-Time Price · USD
0.241
-0.039 (-13.96%)
At close: Apr 28, 2026, 4:00 PM EDT
0.230
-0.011 (-4.56%)
Pre-market: Apr 29, 2026, 5:02 AM EDT
Jaguar Health Revenue
In the year 2025, Jaguar Health had annual revenue of $11.51M, down -1.52%. Jaguar Health had revenue of $3.24M in the quarter ending December 31, 2025, a decrease of -7.81%.
Revenue (ttm)
$11.51M
Revenue Growth
-1.52%
P/S Ratio
0.29
Revenue / Employee
$244,915
Employees
47
Market Cap
3.38M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 11.51M | -178.00K | -1.52% |
| Dec 31, 2024 | 11.69M | 1.93M | 19.75% |
| Dec 31, 2023 | 9.76M | -2.20M | -18.36% |
| Dec 31, 2022 | 11.96M | 7.62M | 175.80% |
| Dec 31, 2021 | 4.34M | -5.05M | -53.81% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionJAGX News
- 1 day ago - Jaguar Health Granted Extension Until May 15, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule; Company Announces Reverse Stock Split - Accesswire
- 4 days ago - Jaguar Health Announces Acceptance of two Late-Breaking Abstracts for Liquid Oral Crofelemer Treatment of Intestinal Failure in Pediatric Patients at the European Society for Pediatric Gastroenterology, Hepatology & Nutrition (ESPGHAN) - Accesswire
- 8 days ago - Jaguar Health Reports Approval of All Proposals at April 2026 Special Meeting of Stockholders - Accesswire
- 15 days ago - Artificial Intelligence (AI) Platforms Could Enhance Jaguar Health's Development and Anticipated Commercialization of Crofelemer for Rare Disease Intestinal Failure (IF) Programs - Accesswire
- 18 days ago - Jaguar Health Earnings Call Transcript: Q4 2025 - Transcripts
- 19 days ago - Reminder: Jaguar Health to Host Investor Webcast at 8:30 am Eastern on Friday, April 10, 2026 Regarding Q4 2025 Financials and Company Updates - Accesswire
- 20 days ago - Jaguar Health Completes Effectiveness Trial to Support FDA Approved Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs - Accesswire
- 21 days ago - Jaguar Health Reports 2025 Financials - Accesswire